【摘要】 目的　定量测定抗人血管内皮生长因子 (VEGF)单抗E1 1 组、生理盐水组荷人颊癌裸鼠血清中VEGF含量并进行比较 ,以观察E1 1 对体内可溶性VEGF水平的影响。方法　接种人颊鳞癌的BALB c裸小鼠分别通过腹腔或瘤周皮下注射E1 1 或生理盐水。接种后第 18天处死 ,收集裸鼠血清 ,采用改进的间接ELISA法定量测定VEGF含量。结果　E1 1 组裸鼠血清中VEGF含量均显著低于生理盐水组 ,其中E1 1 瘤周皮下组VEGF水平最低 ,仅 (1 17±0 13) μg L。结论　抗人VEGF单抗是通过中和VEGF而阻断其发挥促肿瘤血管生成的作用 ,从而产生抑瘤效应。荷人颊癌裸鼠血清中VEGF的水平与其荷瘤的瘤重呈正相关关系 ,提示恶性肿瘤患者血清中的VEGF是新的肿瘤标志物。更多还原

【Abstract】 Objective Quantitative study of the effect of anti-human VEGF mAb E-{11} to VEGF level in serum of nude mice transplanted buccal carcinoma.Methods E-{11} was administered into BALB/c nu/nu mice which were transplanted human buccal carcinoma. The saline was administrated as negative control. Mice were killed at 18 days. The VEGF level in serum of mice was determined by improved indirect ELSIA.Results Compared with the VEGF level in serum of mice in saline group, it was dramatically decrease in E-{11} group. The VEGF level in serum of mice treated E-{11} by subcutaneous was lowest and only reached (1.17±0.13) μg/L.Conclusion It demonstrated that the anti-human VEGF mAb could reduce the VEGF level in serum by binding VEGF, and block its biological activity. It indicates that VEGF in serum of malignant tumor patient is a new tumor marker.更多还原